Navigation Links
Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
Date:12/5/2008

REHOVOT, Israel and JERSEY CITY, New Jersey, December 5 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), an innovative molecular diagnostic company leveraging microRNAs as biomarkers, reported today its consolidated financial results for the quarter ended September 30, 2008 and business highlights.

The company recorded revenues for the third quarter of 2008 of $705,000. These revenues were recorded from the date of acquisition of Parkway Clinical Laboratories at the end of July through September 30, 2008. The company reported a 2008 third-quarter net loss of $3.0 million, or $0.25 per ordinary share. The third-quarter result compares with a net loss of $2.2 million, or $0.18 per ordinary share, for the corresponding quarter of 2007. Net loss for the nine months ended September 30, 2008 was $10.6 million, or $0.88 per ordinary share, compared with a net loss of $6.4 million, or $0.59 per ordinary share, for the corresponding period of 2007.

"This has been a very busy quarter for us at Rosetta Genomics, as we near the introduction to the market of the first molecular diagnostic tests based on our technology." said Amir Avniel, President and CEO of Rosetta Genomics. "As part of our goal to become a leading player in the molecular diagnostic field, introducing innovative tests using our proprietary microRNA technologies, we have initiated a blood based cancer detection development program. These tests will potentially use microRNAs extracted from a simple blood draw, and provide a minimally-invasive detection and screening tool for both patients and physicians. We have already identified microRNAs in serum, and are now advancing several diagnostic programs based on these findings.

We believe that given their minimally invasive nature, as well as other important advantages, blood-based micro
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
2. /C O R R E C T I O N -- Rosetta Genomics Ltd/
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
4. Rosetta Genomics to Present at Oppenheimers 19th Annual Healthcare Conference
5. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
6. Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative
7. Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
8. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
9. Rosetta Genomics Reports Second Quarter 2008 Financial Results
10. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
11. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013 Patheon Inc ., a ... the global pharmaceutical industry, will host a complimentary webinar ... Testing” on Tuesday, June 4, 2013 at 11 a.m. ... required to comply with regulations for cleaning validation. ... scientific underpinning and little evaluation of risk. Some ...
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan ... human cord blood stem cell banking and therapeutics, announced ... the No. 16 Acorn Stairlifts Indy car driven by ... the remainder of the IZOD IndyCar 2013 season.   ... will work to support awareness of umbilical cord blood ...
(Date:5/23/2013)... MA (PRWEB) May 23, 2013 ... inch wide and provide 15 mm travel range ... The small dimensions make these new positioners ... confined spaces. A vacuum rated version is also ... Drawings, specifications and datasheets can be found at: ...
(Date:5/23/2013)... HILLS, Calif. , May 23, 2013  Saddleback ... recently became the first hospital on the ... robotic technology. This new surgical option provides women with ... Marc Winter , M.D., ... gynecologist and surgeon and medical director of minimally invasive ...
Breaking Biology Technology:Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3
... Belgium and LUND, Sweden, February 23 , ... of Partial Factor VIII Inhibition in,Patients Undergoing Knee Replacement ... Brussels: THR) and co-development partner,BioInvent International (OMXS: BINV) announce ... Phase II trial with their long-acting anticoagulant,TB-402 for the ...
... Approval and CommercializationSEATTLE, Feb. 20 Cell Therapeutics, Inc. ... exercised its option to sell its 50% ownership interest ... (Spectrum) for $18 million. CTI and Spectrum established a ... Zevalin. At that time CTI contributed all of the ...
... Feb. 20 Bariatric surgeons at Central,Baptist Hospital made ... procedure to decrease the capacity of a patient,s,stomach without ... the first,incisionless procedure of its kind performed in the ... Peter M. Denk, M.D., performed the procedure, dubbed,POSE (Primary ...
Cached Biology Technology:ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 2ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 3ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 4ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 5Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million 2Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million 3Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million 4Surgeons Perform First Incisionless Bariatric Procedure in the United States 2
(Date:5/22/2013)... durability in fuel cell powered buses, including a ... between electrode degradation processes and bus membrane durability. ... electrode degradation stressors in the operating cycle of ... findings of the study, led by SFU graduate ... long-term study at Burnaby-based Ballard Power Systems and ...
(Date:5/22/2013)... streamlined approach to genetic engineering drastically reduces the ... into bacteria, the workhorses of biotechnology, scientists are ... Biology , the method paves the way for ... development, environmental cleanup and other activities. , Keith ... a piece of the genetic material DNA into ...
(Date:5/22/2013)... details on how climate change will affect interactions between ... Journal of Animal Ecology . This knowledge, they ... policymakers of how species are likely to be impacted ... growing recognition among biologists that climate change is affecting ... is going to have very important consequences for the ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5
... and streams in remote parts of the UK, southern ... brown by dissolved organic matter. In this weeks Nature ... from UCL (University College London) and the US Environmental ... indicative of a return to a more natural, pre-industrial ...
... Haven, Conn. The gigantic fossil claw of an 390 ... arthropods spiders, insects, crabs and the like were ... scorpion, said O. Erik Tetlie , postdoctoral associate in ... and an author of the report online in Royal Society ...
... being important for the design of nature reserves, assessing ... options for land use. Most present-day analyses suffer from ... closer together in space are more likely to have ... may critically bias model predictions. A new study in ...
Cached Biology News:Don't judge a brook by its color -- brown waters are more natural 2
...
...
... 3501 XL Power Supply, 1. 3500 V, ... current, constant power, and linear voltage ramp ... focused equilibrium in IPG strips quickly without ... for variations in gel thickness, sample ionic ...
Request Info...
Biology Products: